Share on StockTwits
 

KYTHERA Biopharmaceuticals (NASDAQ:KYTH) CFO John W. Smither sold 1,125 shares of the stock on the open market in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $42.54, for a total transaction of $47,857.50. Following the completion of the transaction, the chief financial officer now directly owns 10,200 shares of the company’s stock, valued at approximately $433,908. The transaction was disclosed in a filing with the SEC, which is available at this link.

Shares of KYTHERA Biopharmaceuticals (NASDAQ:KYTH) traded up 3.38% on Tuesday, hitting $44.00. The stock had a trading volume of 331,062 shares. KYTHERA Biopharmaceuticals has a 52 week low of $14.07 and a 52 week high of $47.85. The stock’s 50-day moving average is $38.99 and its 200-day moving average is $35.99. The company’s market cap is $941.6 million.

KYTHERA Biopharmaceuticals (NASDAQ:KYTH) last announced its earnings results on Thursday, November 14th. The company reported ($0.62) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.72) by $0.10. Analysts expect that KYTHERA Biopharmaceuticals will post $-2.74 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on KYTH shares. Analysts at FBR & Co. initiated coverage on shares of KYTHERA Biopharmaceuticals in a research note to investors on Wednesday, October 30th. They set an “outperform” rating on the stock. Separately, analysts at FBR Capital Markets initiated coverage on shares of KYTHERA Biopharmaceuticals in a research note to investors on Wednesday, October 30th. They set an “outperform” rating and a $58.00 price target on the stock. Finally, analysts at Bank of America Corp. initiated coverage on shares of KYTHERA Biopharmaceuticals in a research note to investors on Friday, October 25th. They set a “buy” rating on the stock. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. KYTHERA Biopharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $45.33.

KYTHERA Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of prescription products for the aesthetic medicine market.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.